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ABSTRACT

PKA AS AN UPSTREAM KINASE FOR LKB1/STRAD/MO25

Seth T. Herway
Department of Physiology and Developmental Biology
Doctor of Philosophy

The LKB1/STRAD/MO25 complex (LSMK) has been identified as the major
upstream kinase for AMP-activated protein kinase (AMPK). PKA phosphorylates
LKB1 at the Ser428 residue in humans and Ser431 residue in mice. We investigated
PKA as an upstream kinase for LSMK. LKB1 that had been incubated with PKA
prior to incubation with AMPK experienced up to a 51% increase in AMPK Kinase
activity compared to LKB1 alone (p < 0.05). When blocked with a PKA Inhibitor,
the kinase effect of PKA on LKB1 was eliminated. Rat epitrochlearis muscle tissue
incubated with epinephrine experienced no increase in AMPK activity compared with
controls indicating that epinephrine does not cause AMPK activity in this type of
tissue. In conclusion, phosphorylation by PKA can increase the AMPKK activity of
LKB1-STRAD-MO25 in vitro. Because LKB1 has been found to be constitutively
active, it is postulated that phosphorylation by PKA may act to enhance LKB1-AMPK
interaction and thus achieve its effect.
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Prospectus
Introduction
The 5’-AMP-Activated protein kinase (AMPK) is a master metabolic regulator
responsible for directing cellular responses to an energy challenge. AMPK is
hypothesized to phosphorylate proteins involved in both fatty acid oxidation and
glucose uptake. AMPK exerts these effects so as to generate ATP, while switching off
biosynthetic pathways that consume ATP. In this manner it functions as an energysensing molecule that directs the body to a homeostatic energy condition. The roles of
AMPK in glucose uptake and fatty acid oxidation, as well as other proposed roles in
mitochondrial biogenesis and increased insulin sensitivity, have directed significant
attention to discovering how activation of AMPK occurs within the body. This study
will explore the role of Protein Kinase A (PKA) in the biochemical phosphorylation
cascade that results in activation of AMPK.

Activation of AMPK
AMPK is composed of three subunits, denoted α, β, and γ. The α subunit is the
catalytic subunit of the enzyme and the β and γ subunits are non-catalytic (1, 2, 3, 4).
Each subunit has multiple isoforms; there exists two for the alpha subunit, two for the
beta subunit, and three for the gamma subunit. When the alpha subunit is
phosphorylated at the threonine 172 amino acid residue, the AMPK molecule is
activated (5, 6, 7). The gamma subunit has four Cystathione Beta Synthase (CBS)
domains that come together to form two AMP binding sites. Binding of the first AMP
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allows for binding of the second which exposes the kinase domain on the alpha
subunit, making it available for phosphorylation at threonine 172. AMPK is
dephosphorylated and deactivated by Protein Phosphatase 2-A (PP2A). A higher
AMP/ATP ratio makes AMPK a better substrate for phosphorylation by AMPK kinase
(AMPKK) and a poorer substrate for phosphatases.
AMPKK and AMPK can also be activated artificially by use of the chemical 5aminoimidazole-4-carboxamide-riboside (AICAR) (8, 9, 10, 11, 12, 13). AICAR was
reported to be taken up by the cells and phosphorylated to form an AMP analog, ZMP,
which then activated AMPKK and AMPK in the same manner as AMP.
AMPK is activated by muscle contraction (25), electrical stimulation in situ
(27), and contraction of isolated muscles in vitro (28).

Regulation of Fatty Acid Oxidation by AMPK
AMPK exerts its effects of fatty acid oxidation by inactivating acetyl-CoA
carboxylase (ACC) (14, 15, 16). Active AMPK phosphorylates ACC and thereby
inhibits its activity. By inactivating ACC the amounts of malonyl-CoA in the cell are
decreased because active ACC converts acetyl-CoA to malonyl-CoA. Malonyl-CoA
inhibits carnitine-palmitoyl-acyl-transferase-1 (CPT-1) which is rate limiting for
transport of fatty acids into the mitochondria for oxidation and use as fuel. Thus
activation of AMPK results in less active ACC and therefore less inhibition by CPT-1
of fatty acids into the mitochondria, resulting in increased fatty acid oxidation.
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Regulation of Glucose Uptake by AMPK
The insulin-sensitive glucose transporter, GLUT-4, resides in two locations in
the muscle (17, 18, 19, 20). In the basal or low insulin state, the GLUT-4 transporters
reside in microvesicles beneath the sarcolemma and T-tubule membranes. In response
to insulin or contraction, these transporters are translocated to the membranes of the T
tubules and sarcolemma, thus increasing the capacity for moving glucose into the
muscle fiber. AMPK has been identified as the mediator of contraction-induced
translocation of GLUT-4 from the microvesicle to the membrane (30, 31, 32, 33).

The Role of LKB1 as an AMPKK
In 2003 researchers at the University of Dundee determined that endogenous
and recombinant complexes of LKB1, STRADalpha/beta, and MO25alpha/beta
activate AMPK via phosphorylation of Thr172, thus functioning as an AMPK kinase
(AMPKK) in this manner (21). LKB1 is a serine/threonine kinase that was discovered
originally as the product of the gene mutated in Peutz-Jegher syndrome (22, 23). The
researchers found that size-exclusion chromatography from rat liver extracts eluted
AMPKK1 and AMPKK2. Blotting antibodies against LKB1, STRADalpha, and
MO25 alpha revealed the activity of AMPKK2 correlated with the presence of LKB1,
STRADalpha, and MO25alpha. There was also a weaker signal for LKB1,
STRADalpha, and MO25alphs in AMPKK1. AMPKK activity was
immunoprecipitated from both AMPKK1 and AMPKK2 .The ability of the AMPKK1
and AMPKK2 fractions to activate AMPK was almost completely eliminated by
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immunoprecipitation with anti-LKB1 antibody but not a control immunoglobin. The
researchers also showed that STRADalpha and MO25alpha are necessary to generate
an active complex because the amount of active LKB1 was limited by the availability
of STRADalpha and MO25 alpha. It has been determined that LKB1 has an absolute
requirement for STRAD for catalytic activity and this activity is enhanced by binding
to MO25 which is thought to act as a scaffolding protein (24).

Characterization of LKB1 and its role as an AMPKK
The role of LKB1 as an upstream AMPK kinase is not yet clearly defined. It
has been shown that AMPKK activity increases with increasing exercise intensity and
duration in humans (34). The increase in AMPKK activity was directly related to the
increase in AMPKalpha1 activity but much less than that of the alpha2 isoform.
Another study demonstrated that LKB1 in skeletal muscle was not activated by
electrical stimulation induced contraction, AICAR, or phenformin (35). Identification
of the exact mechanisms and regulation of AMPKK may shed further light on its role
in the metabolic regulation that is mediated by AMPK.

LKB1 as a Master Kinase
Recently it was reported that the LKB1-MO25-STRAD complex
phosphorylates eleven of the twelve AMPK-related kinases NUAK1, NUAK2,
BRSK1, BRSK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, and MARK4, but not
MELK (25). The function of many of these proteins are still unclear. Activity of many
of these AMPK-related kinases resulted in a greater than fifty fold increase in activity
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upon phosphorylation by LKB1. The authors suggest that LKB1 functions as a master
kinase for AMPK and AMPK-related kinases.

PKA and AMPK Actions in the Body
There are a number of physiologic actions in which increased cellular
concentrations of PKA occur simultaneously with phosphorylation and activation of
AMPK. In the liver, cellular PKA concentrations are elevated when glucagon and
catcholamines are at higher levels in the body and insulin is depressed. Under these
conditions glycogen synthesis is inhibited and glycogenolysis is stimulated. It is
under the same conditions that higher levels of activated AMPK would be expected to
be observed in the cell. The actions of glucagon on liver tissue may be analogous to
what is observed in muscle tissue. One of the best characterized actions of glucagon is
elevation of intracellular cAMP and subsequent activation of PKA (37). It is possible
that high concentrations of PKA in muscle tissue may lead to activation of AMPK.
The inactivation of ACC, which is mediated by AMPK, is also induced by
increased PKA levels due to the actions of glucagons. The parallel actions of both
AMPK and PKA in the inactivation of ACC provides further reason to investigate
possible correlations between the two proteins.
The beta-adrenergic signaling pathway represents a prime regulator of
triglyceride breakdown, acting by the accumulation of cAMP and subsequent PKAdependent phosphorylation of hormone-sensitive lipase (HSL). The activity of HSL is
regulated by both phosphorylation and translocation to the lipid droplet (40). PKA
phosphorylates HSL at Ser563, Ser659, and Ser660. Ser563 is suspected to be the key
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residue phosphorylated for HSL activation. It has been reported that AMPK
phosphorylates HSL at Ser565 in vitro without any direct effect on HSL activity, but
this abolished the further phosphorylation of HSL by PKA at Ser563 (41). Research
has been done to support the idea that B-adrenergic agents activate AMPK via an
intermediary rise in cAMP (and therefore PKA) and that this serves to enhance the
lipolytic rate as mediated by AMPK (37). This relationship between PKA and AMPK
as seen in the effects of beta-adrenergic agents may also indicate a relationship
between the two in muscle tissue.

PKA Regulates LKB1 Activity
PKA phosphorylates LKB1 at the serine 431 residue (38). LKB1 is a tumor
suppressor protein that regulates cell proliferation and polarity (39). LKB1 terminates
with a functional prenylation motif following Ser431 of Ala-Cys-Lys-Gln-Gln. It has
been demonstrated that phophorylation of LKB1 at Ser431, but not its farnesylation at
Cys433, is very likely to be significant in the mediation of the ability of LKB1 to
suppress cell growth (36). Mutation of Ser431 blocked the ability of LKB1 to
suppress cell growth in a tumor line that does not normally express LKB1. Mutation
of Cys433 had no such effect. Mutating Cys433 to alanine blocked membrane
localization while phosphorylation of Ser431 by PKA had no localization effect.

Hypothesis
Just as PKA may mediate the tumor suppression activity of LKB1 by
phosphorylation at Ser431, it may also serve to enhance its AMPKK activity in the
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same manner. It is hypothesized that LKB1 phosphorylated by PKA at Ser431 would
result in increased AMPKK activity of LKB1 and suggest a possible role for PKA as
an AMPKK kinase (AMPKKK).

Proposed Experiments
1) The appropriate antibody for detecting phosphorylated LKB1 by PKA must
first be determined. Varying concentrations of PKA will be incubated with an
LKB1/MO25/STRAD preparation. The reaction will be stopped with
Laemmli’s buffer after varying amounts of time. The reaction mixture will
then be subjected to a Western Blot for determination of the degree of
phosphorylation of LKB1 by PKA. Antibodies from Cell Signaling
Technology for LKB1 (Ser428), Immunuquest for LKB1 (Ser431), and Santa
Cruz Biotechnology for LKB1 (Ser431) will be tested and the most accurate
and efficient antibody will be determined. These experiments will also aid in
elucidating appropriate amounts of PKA and LKB1 to use in reaction mixtures.
2) Activity assays will be performed to determine the phosphorylative effects of
PKA on the SAMS and AMARA peptides in order to ascertain whether
activity assays can be used in conjunction with PKA or if the PKA will
phosphorylate one of the peptides under consideration and obscure the results
of all assays.
3) A series of two-step activity assays will be performed in which PKA is
incubated with LKB1 sufficiently to phosphorylate the protein as determined
by results of Experiment 1. Phosphorylated LKB1 will then be incubated with
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AMPK and the degree of phosphorylation of AMPK will be determined. The
concentrations of LKB1, PKA, and AMPK as well as the times of incubation
will be varied in order to determine the requirements for full AMPK activation.
4) Western blots will then be performed to validate the results of Experiment 3.
5) The series of two-step assays conducted in Experiment 3 will be confirmed by
assays using a PKA Inhibitor (Sigma Aldrich) to validate that the effects
observed were occurring as a result of PKA and not another element in the
reaction mixture.
6) PKA Inhibitor (Sigma Aldrich) will also be used in a two-step assay involving
PKA and LKB1. PKA and LKB1 will be incubated to allow for
phosphorylation of LKB1 by PKA. PKA Inhibitor will then be used to inhibit
residual PKA and AMPK will then be added to the reaction mix. In this
manner the interference of residual PKA in the phosphorylation of AMPK by
LKB1 can be determined.
7) The efficacy of the PKA Inhibitor used in Experiment 6 and 7 will be validated
with activity assays by determining phosphorylative effects of PKA with and
without the inhibitor using KempTide (Upstate), a substrate for
phosphorylation by PKA.
8) Rat epitrochlearis will be subjected to varying concentrations of AICAR,
epinephrine and combinations thereof. Exposure to said compounds will
increase the concentrations of PKA in the muscle. The tissue will then be
homogenized and studied by western blot to determine the degree to which
ACC, AMPK, and LKB1 were activated/inactivated due to this elevated
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concentration of PKA in the muscle. Results of this experiment will be
compared with the results of previous in vitro experiments.
9) Kemptide will be used with the rat epitrochlearis tissue in Experiment 8 to
verify that there were increased levels of PKA in the tissue when exposed to
epinephrine. The effect of AICAR on PKA tissue concentrations will also be
measured.
10) An immunoprecipitation assay using G-Sepharose protein on the rat
epitrochlearii will be performed in order to verify the AMPK activity in the
muscle. This will then potentially be correlated with the hypothetical increases
in PKA and LKB1 phosphorylation resulting from the treatments with AICAR
and epinephrine.

Methods
Buffers. Dithiothreitol (DTT), AMP, ATP, [γ32]ATP, 4-(2-Aminoethyl)Benzenesulfonyl Fluoride (AEBSF), benzamidine, leupeptin, soybean trypsin
inhibitor, and AMARA peptide (Zinsser, UK) will be added just prior to use when
included. Tissue Homogenization Buffer: 50 mM Tris-HCl, 250 mM Mannitol, 50 mM
NaF, 5 mM Sodium Pyrophosphate, 1 mM EDTA, 1mM EGTA, 1 % Triton X-100,
with or without 10% glycerol v/v, 1 mM benzamidine, 1 µg/ml soybean trypsin
inhibitor, 1 mM DTT, 0.2 mM AEBSF, pH 7.4 at 4˚C. AMPKK Homogenization
Buffer: As with Tissue Homogenization Buffer but with 100 µM leupeptin. AMPK
Storage Buffer: 50 mM Tris-HCl, 250 mM Mannitol, 1 mM EDTA, 1mM EGTA, 1
mM DTT, 0.02% (w/v) Brij-35, 10% v/v glycerol, pH 7.4 at 4˚C. Laemmli’s Buffer:
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(30). AMPKK Assay Buffer: 100 mM Hepes, 200 mM NaCl, 20% glycerol, 2 mM
EDTA, 12.5 mM MgCl2, 0.5 mM AMP, 0.5 mM ATP, 2.0 mM DTT, pH 7.0.
Phosphorylation Buffer: 40 mM Hepes, 80 mM NaCl, 8% glycerol, 0.8 mM EDTA,
0.8 mM DTT, 5 mM MgCl2, 0.2 mM AMP, 0.2 mM ATP, 0.33 mM AMARA peptide,
0.133 µCi/µl [γ32]ATP, pH 7.0. PBS: 140 mM NaCl, 2.7 mM KCl, 2.1 mM KH2PO4,
9.9 mM Na2HPO4, pH 7.3. PBST: PBS with 1% Tween-20 (Calbiochem).
AMPKK Activity Assays. Activation of AMPK will be measured by 32P
incorporation from [γ32]ATP into SAMS or AMARA peptide. Depending on the assay,
PKA (2 ul ) and/or LKB1 (2 µl) will be incubated with AMPKK Assay Buffer (4 µl)
and rAMPK in Storage Buffer (4 µl) for varying periods. Phosphorylation Buffer (15
µl) will be added and the reaction will be stopped by spotting 1 sq cm pieces of P81
filter paper (Whatman; Tewksbury, MA) with the final reaction mixture (15 µl). With
Kemptide or LKB1tide assays, the AMARA or SAMS peptide in the Phosphorylation
Buffer will be replaced with 0.775 mM Kemptide or LKB1tide. Filter papers will be
washed 6 x 90 sec in 100 ml 1% phosphoric acid, rinsed with acetone, dried, and
counted for 1 minute in 3 ml Ecolite (ICN; Irvine, CA).
PKA Abundance Assay. To measure the abundance of PKA in rat epitrochlearis
muscle tissue, the tissues will be diluted 1:9 (v/v) in Homogenization Buffer with 0.5
mM 3-isobutyl-1-methylxanthine for phosphodiesterase inhibition. Diluted tissue
homogenates will be incubated with AMPKK Assay Buffer and Phosphorylation
Buffer. The AMARA peptide in the Phosphorylation Buffer will be replaced with
0.775 mM Kemptide. The reaction will be stopped by spotting 1 sq cm pieces of P81
filter paper (Whatman; Tewksbury, MA) with the final reaction mixture (15 ul). Filter
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papers will be washed 6 x 90 sec in 100 ml 1% phosphoric acid, rinsed with acetone,
dried, and counted for 1 minute in 3 ml Ecolite (ICN; Irvine, CA).
Western Blots. Homogenates will be diluted in 4 x Laemmli’s buffer and water
(1:1:2) and then separated by SDS-PAGE at 200 V for 35 minutes in 7.5% Tris-HCl,
50 µl well, Ready Gels (Bio-Rad Hercules, CA). Proteins will be transferred from the
gels to nitrocellulose membranes at 100 V for 50 min. Membranes will then be
blocked in PBST and 5% Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad) for 1h.
Membranes will be incubated overnight at 4 C in PBST, 5% blocking milk, and first
antibodies. After incubation with the first antibody, membranes will be washed twice
with PBST for 10 minutes and twice with PBS for 5 minutes. Membranes will then be
incubated for 1h at room temperature in PBST, 3% blocking milk, and a second
antibody. Following incubation with the second antibody, membranes will be washed
twice with PBST for 10 minutes and twice with PBS for 5 minutes. Membranes will
then be covered with ECL Western Blotting Detection Reagent (Amersham
Pharmacia), enclosed in plastic wrap, and visualized on Hyperfilm ECL High
Performance Chemiluminescence film (Amersham Pharmacia). Relative amounts of
protein will be quantified by measuring spot size and intensity with AlphEaseFC
Software (Alpha Innotech; San Leandro, CA).
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Abstract
The LKB1/STRAD/MO25 complex (LSMK) has been identified as the major
upstream kinase for AMP-activated protein kinase (AMPK). PKA phosphorylates
LKB1 at the Ser428 residue in humans and Ser431 residue in mice. We investigated
PKA as an upstream kinase for LSMK. LKB1 that had been incubated with PKA
prior to incubation with AMPK experienced up to a 51% increase in AMPK Kinase
activity compared to LKB1 alone (p < 0.05). When blocked with a PKA Inhibitor,
the kinase effect of PKA on LKB1 was eliminated. Rat epitrochlearis muscle tissue
incubated with epinephrine experienced no increase in AMPK activity compared with
controls indicating that epinephrine does not cause AMPK activity in this type of
tissue. In conclusion, phosphorylation by PKA can increase the AMPKK activity of
LKB1-STRAD-MO25 in vitro. Because LKB1 has been found to be constitutively
active, it is postulated that phosphorylation by PKA may act to enhance LKB1-AMPK
interaction and thus achieve its effect.

Key Words: AMPK, AMPKK, PKA, Epinephrine, LKB1
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Thesis
Introduction
The 5’-AMP-Activated protein kinase (AMPK) is a master metabolic regulator
responsible for directing cellular responses to energy challenges (9). AMPK
phosphorylates acetyl CoA carboxylase (ACC) to promote fatty acid oxidation (21, 24,
26, 31) and other proteins to achieve insulin-independent glucose uptake (2, 6, 18).
AMPK exerts these effects so as to generate ATP, while switching off biosynthetic
pathways that consume ATP. In this manner it functions as an energy-sensing
molecule that directs the body to a homeostatic energy condition. AMPK is activated
by metformin, a commonly prescribed antidiabetic drug, which is thought to function
by activating AMPK in the liver and muscle (36). The roles of AMPK in glucose
uptake, fatty acid oxidation, and diabetic treatments, as well as other proposed roles in
mitochondrial biogenesis and increased insulin sensitivity, have directed significant
attention to discovering how activation of AMPK occurs within the body (9, 25, 27,
34, 37).
AMPK is phosphorylated and activated by an AMPK kinase (AMPKK). In
2003, a major AMPKK was identified to be LKB1 (STK 11) complexed with mouse
protein 25 (MO25) and the STE-related adaptor protein (STRAD) (10). In muscle
deficient in LKB1, phosphorylation of ACC-2 and glucose uptake were inhibited thus
indicating a role for the LKB1 as an AMPKK in muscle (29). Additionally, mice
lacking LKB1 expression in skeletal muscle had reduced AMPKalpha2 isoform
activity as well as reduced phosphorylation of Thr172 (30).
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LKB1 has been identified as the major AMPK kinase for skeletal muscle, but
how it is regulated is not yet clearly defined. It has been shown that AMPKK activity
increases with increasing exercise intensity and duration in humans (4). The increase
in AMPKK activity was directly related to the increase in AMPKalpha1 activity but
much less than that of the alpha2 isoform. Meanwhile, another study has
demonstrated decreased AMPKK activity in a rat model with training duration and
intensity despite increases in LKB1 protein (32). It has also been demonstrated that
LKB1 in skeletal muscle was not activated by electrical stimulation induced
contraction, AICAR, or phenformin (28). A study investigating AMPKK activity in
trained or nontrained muscle in response to electrical stimulation showed that
AMPKK activity did not increase even though phospho-AMPK did increase (14). This
would suggest that AMPKK is activated during electrical stimulation of both trained
and nontrained muscle by mechanisms other than covalent modification.
Identification of the exact mechanisms and regulation of AMPKK may shed further
light on its role in the metabolic regulation that is mediated by AMPK.
LKB1 is a tumor suppressor protein that regulates cell proliferation and
polarity (3). Mouse LKB1 is composed of 436 residues. LKB1 terminates with a
functional prenylation motif following Ser431 of Ala-Cys-Lys-Gln-Gln. The human
LKB1 protein is 433 residues long and terminates with the same residue sequence as
in mouse tissue. In human tissue, the phosphorylation site is at serine 428. The
catalytic domain is more distantly related to other protein kinases and its N-terminal
and C-terminal non-catalytic domains are not related to any other proteins nor have
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functional domains been detected therein (20). LKB1 has been found to be expressed
in all fetal and adult tissues examined (12, 17).
There is evidence that LKB1 is phosphorylated at Ser31, Ser325, Thr 366, and
Ser431 by upstream kinases. PKA phosphorylates LKB1 at Ser428 in humans and
Ser431 in mice (30). LKB1 has been shown to autophosphorylate at Thr 185, Thr336,
and Ser404 (1). It has been demonstrated that phophorylation of LKB1 at Ser431, but
not its farnesylation at Cys433, is very likely to be significant in the mediation of the
ability of LKB1 to suppress cell growth (30). Mutation of Ser431 blocked the ability
of LKB1 to suppress cell growth in a tumor line that does not normally express LKB1
(line G361). Mutation of Cys433 had no such effect. Mutating Cys433 to alanine
blocked membrane localization while phosphorylation of Ser431 by PKA had no
localization effect. Mutation of Thr336, the major autophosphorylation site, to a Glu,
but not an Ala, prevented LKB1 from inhibiting cell growth in the G361 cell line (31).
The Thr336, Thr366, and Ser431 residues as well as surrounding residues are highly
conserved in mammalian LKB1 (31). The p90 ribosomal S6 protein kinase (RSK) and
Protein Kinase A (PKA) phosphorylate LKB1 at the Ser431 residue (1, 5, 30).
Therefore RSK and PKA may regulate cell growth by phosphorylation of LKB1. This
regulation may extend to the AMPK kinase activity of LKB1.
The beta-adrenergic signaling pathway represents a prime regulator of
triglyceride breakdown, acting by the accumulation of cAMP and subsequent PKAdependent phosphorylation of hormone sensitive-lipase (HSL). The activity of HSL is
regulated by both phosphorylation and translocation to the lipid droplet (13). PKA
phosphorylates HSL at Ser563, Ser659, and Ser660. Ser563 is suspected to be the key
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residue phosphorylated for HSL activation. It has been reported that AMPK
phosphorylates HSL at Ser565 in vitro without any direct effect on HSL activity.
Phosphorylation by AMPK abolished the further phosphorylation of HSL by PKA at
Ser563 (7, 33). Research has been done to support the idea that beta-adrenergic
agents activate AMPK via an intermediary rise in cAMP (and therefore PKA) and that
this serves to enhance the lipolytic rate as mediated by AMPK (35). This relationship
between PKA and AMPK as seen in the effects of beta-adrenergic agents may also
indicate a relationship between the two in muscle tissue.
In the present paper, the effect of phosphorylation of LKB1 by PKA on the
AMPK Kinase activity of LKB1 is reported. Additionally, we report the effect of
increased PKA concentrations induced by exposure to the beta-adrenergic agent
epinephrine on AMPK activation in rat epitrochlearis muscle tissue.

Materials and Methods
Animal care. All procedures were approved by the Institutional Animal Care and Use
Committee of Brigham Young University. Male Wistar rats (Sasco, Wilmington,
MA) were housed in a temperature controlled room (21-22 C) with a 12:12-h lightdark cycle. Rats were fed standard rat chow (Harlan Teklad rodent diet) and water ad
libitum. Rats were anesthetized by intraperitoneal injection of sodium pentobarbital
(45 mg/Kg body wt).
Buffers. Dithiothreitol (DTT), AMP, ATP, [γ32]ATP, 4-(2-Aminoethyl)Benzenesulfonyl Fluoride (AEBSF), benzamidine, leupeptin, soybean trypsin
inhibitor, SAMS peptide and AMARA peptide (Zinsser, UK) were added just prior to
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use when included. Kreb-Henseleit Buffer (KHB): 118.0 mM NaCl, 4.70 mM KCl,
1.18 mM KH2PO4, 1.17 mM MgSO4 (anhydrous), 25.0 mM NaHCO3, 5 mM CaCl2.
Buffer oxygenated with 95% oxygen, 5%, carbon dioxide gas before use. KHB-Gluc
Buffer: 2.8 mM ascorbic acid, 5 mM glucose, and 0.1 % BSA in oxygenated KHB.
KHB-BSA Buffer: 1 mg BSA/ml KHB. Insulin Stock Solution: 1000 mU insulin in
KHB-BSA Buffer. Tissue Homogenization Buffer: 50 mM Tris-HCl, 250 mM
Mannitol, 50 mM NaF, 5 mM Sodium Pyrophosphate, 1 mM EDTA, 1mM EGTA, 1
% Triton X-100, with or without 10% glycerol v/v, 1 mM benzamidine, 1 µg/ml
soybean trypsin inhibitor, 1 mM DTT, 0.2 mM AEBSF, pH 7.4 at 4˚C. Buffer C: like
muscle homogenization buffer but without NaF, sodium pyrophosphate, benzamidine,
soybean trypsin inhibitor, and AEBSF. AMPK Storage Buffer: 50 mM Tris-HCl, 250
mM Mannitol, 1 mM EDTA, 1mM EGTA, 1 mM DTT, 0.02% (w/v) Brij-35, 10% v/v
glycerol, pH 7.4 at 4˚C. Laemmli’s Buffer: (30). AMPKK Assay Buffer: 100 mM
Hepes, 200 mM NaCl, 20% glycerol, 2 mM EDTA, 12.5 mM MgCl2, 0.5 mM AMP,
0.5 mM ATP, 2.0 mM DTT, pH 7.0. Phosphorylation Buffer: 40 mM Hepes, 80 mM
NaCl, 8% glycerol, 0.8 mM EDTA, 0.8 mM DTT, 5 mM MgCl2, 0.2 mM AMP, 0.2
mM ATP, 1.0 mM SAMS peptide, 0.133 µCi/µl [γ32]ATP, pH 7.0.
Immunoprecipitation Buffer: 50 mM Tris-HCl, 150 mM NaCl, 50 mM NaF, 5 mM Na
pyrophosphate, 1 mM EDTA, 1mM DTT, 1 mM benzamidine, 0.1 mM PMSF, 5
ug/ml soybean trypsin inhibitor, pH 7.4. Lysate Assay Buffer: 62.5 mM Na HEPES,
62.5 mM NaCl, 62,5 mM NaF, 6.25 mM pyrophosphate, 1.25 mM EDTA, 1.25 mM
EGTA, 1mM DTT, 1mM benzamidine, 0.1 mM PMSF, 5 ug/ml SPTI. PBS: 140 mM
NaCl, 2.7 mM KCl, 2.1 mM KH2PO4, 9.9 mM Na2HPO4, pH 7.3. PBST: PBS with 1%
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Tween-20 (Calbiochem). Immunoprecipited AMPK Cocktail: 0.1 ml of SAMS peptide
was added to 0.20 ml of 100 mM Hepes, 200 mM NaCl, 20% glycerol, 2 mM EDTA,
12.5 mM MgCl2, 0.5 mM AMP, 2 mM DTT, 0.5 mM ATP, pH 7.0.
Materials. Reagents were obtained from Sigma-Aldrich Chemical (St. Louis, MO)
unless otherwise stated. Recombinant LKB1-STRAD-MO25 lot #28144 (0.1 µg/µl,
34 units/mg) (AMPKK), LKB1tide, and Kemptide were obtained from Upstate
(Charleston, VA). Anti-phospho Threonine-172 AMPK (P-AMPK) and anti-phospho
Serine-431 LKB1 (P-LKB1) antibodies were obtained from Cell Signaling (Beverly,
MA).
Tissue Treatment. Epitrochlearis muscle tissue (average weight 29.2 +/- 1.4 mg) was
extracted from each rat and incubated for 45 minutes in one of six solutions
immediately followed by clamp freezing and storage at -95 C. (1) The control group
was incubated 100 µU insulin in KHB-Gluc Buffer. (2) The AICAR group was
incubated in a solution of 2 mM AICAR and 100 µU insulin in KHB-Gluc Buffer.
(3) The 1 uM Epi group was incubated in 100 µU insulin and 1 uM epinephrine in
KHB-Gluc Buffer. (4) The 1 uM Epi + AICAR group was incubated in 100 µU
insulin, 2 mM AICAR, and 1 uM epinephrine in KHB-Gluc Buffer. (5) The 25 nM
Epi group was incubated in 100 µU insulin and 25 nM epinephrine in KHB-Gluc
Buffer. (6) The 25 nM Epi + AICAR group was incubated in 100 µU insulin, 2 mM
AICAR, and 25 nM epinephrine in KHB-Gluc Buffer.
AMPKK Activity Assays. AMPKK activity was measured by quantitating the
increase in AMPK activity over time. The AMPK activity was measured by 32P
incorporation from [γ32]ATP into SAMS peptide (10). LKB1 was incubated with
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AMPKK Assay Buffer and rAMPK in Buffer C for 15 minutes. In assays determining
the AMPKK activity of PKA, PKA was incubated with rLKB1 for 30 minutes prior to
incubation with rAMPK and Buffer C for 15 minutes. All incubation times were
determined by experimentally defining the kinetics of the reaction and by incubating
for the period during which phosphorylation was linear as a function of time.
Phosphorylation Buffer was added to start the second step of the assay. Following a
10 minute incubation, the reaction was stopped by spotting 1 sq cm pieces of P81 filter
paper (Whatman; Tewksbury, MA) with the final reaction mixture (15 µl). After
waiting 20 sec for complete absorption, filter papers were placed in 1% phosphoric
acid and then washed 6 x 90 sec in 100 ml of the acid, rinsed with acetone, dried, and
counted for 1 minute in 3 ml Ecolite (ICN; Irvine, CA).
PKA Phosphorylation Assay. To determine the amount of phosphorylation by PKA
and the efficacy of PKA inhibitor, Kemptide, a substrate for PKA phosphorylation,
was used. Where Inhibitor was used, PKA in Buffer C was incubated with the
Inhibitor in Buffer C for 30 min prior to beginning of assay. Phosphorylation Buffer
with the 1.0 mM SAMS replaced with 0.775 mM Kemptide was then added to the
mixture to start the reaction. Following a 20 minute incubation, the reaction was
stopped by spotting 1 sq cm pieces of P81 filter paper (Whatman; Tewksbury, MA)
with the final reaction mixture (15 µl). After waiting 20 sec for complete absorption,
filter papers were placed in 1% phosphoric acid and then washed 6 x 90 sec in 100 ml
of the acid, rinsed with acetone, dried, and counted for 1 minute in 3 ml Ecolite (ICN;
Irvine, CA).
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Western Blots. Homogenates were diluted in 4x Laemmli’s buffer and water (1:1:2)
and then separated by SDS-PAGE at 200 V for 35 minutes in 7.5% Tris-HCl, 50 µl
well, Ready Gels (Bio-Rad Hercules, CA). All blots that did not use tissue
homogenates and involved incubation of proteins to achieve phosphorylation were
stopped with 10 ul of 4x Laemmli’s buffer and then loaded into gels. Blots for pACC
were done in 5% gels, respectively. Proteins were transferred from the gels to
nitrocellulose membranes at 100 V for 50 min. Membranes were then blocked in
PBST and 5% Blotting Grade Blocker Non-Fat Dry Milk (Bio-Rad) for 1h. Following
blocking, membranes were incubated overnight at 4 C in PBST, 5% blocking milk,
and first antibodies. After incubation with the first antibody, membranes were washed
twice with PBST for 10 minutes and twice with PBS for 5 minutes. Membranes were
then incubated for 1h at room temperature in PBST, 3% blocking milk, and a second
antibody. Following incubation with the secondary antibody, membranes were
washed twice with PBST for 10 minutes and twice with PBS for 5 minutes.
Membranes were then be covered with ECL Western Blotting Detection Reagent
(Amersham Pharmacia), enclosed in plastic wrap, and visualized on Hyperfilm ECL
High Performance Chemiluminescence film (Amersham Pharmacia). Relative
amounts of protein were quantified by measuring spot size and intensity with
AlphEaseFC Software (Alpha Innotech; San Leandro, CA).
Immunoprecipitation. AMPK activity was determined by performance of
immunoprecipitation as previously reported (22).
Statistics. A Student’s t-test was used to determine the effect on phosphorylation of
AMPK upon incubation with LKB1 alone and incubation with LKB1 that has been
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phosphorylated by 0.10 units of PKA as shown in Figure 3. All other experiments
were analyzed for significance using a one-way analysis of variance (ANOVA).
When effects were significant, the Fisher’s LSD multiple comparison test was used to
determine the location. Statistical significance was set at p < 0.05 for all tests. All
statistical procedures were performed with the NCSS statistical program (Kaysville,
Utah). All data are reported as means +/- standard errors (SEM).

Results
To test the hypothesis that phosphorylation of LKB1 by PKA may increase the
AMPKK activity of LKB1, we first incubated PKA with LKB1 and blotted for
phosphoserine428-LKB1 (P-LKB1) to determine if LKB1 is phosphorylated by PKA
at this residue. Two, 0.10, and 0.04 units of PKA as well as a buffer solution were
incubated with LKB1. Maximal phosphorylation of LKB1 occurred with 0.10
phosphorylating units of PKA (Figure 1, n=6, p < 0.05).
To determine if LKB1 phosphorylated by PKA increases the AMPKK activity
of LKB1, PKA (0.10 unit) was incubated with LKB1 as performed in the experiment
shown in Figure 1. The phosphorylated LKB1 mixture was then incubated with
AMPK and assayed using a SAMS peptide substrate to determine if additional
phosphorylation of AMPK occurred. LKB1 that had been phosphorylated by 0.10
units of PKA prior to incubation with AMPK showed significantly more AMPKK
activity than LKB1 alone (Figure 2, n=12, p < 0.05). The 0.10 unit mixture produced
a 33% increase in phosphorylation compared to controls.
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These results were then validated with a western blot for phosphothreonine172 AMPK (P-AMPK) when LKB1 was incubated with AMPK having had prior
incubation with 0.10 unit of PKA. Again, significant additional phosphorylation was
seen with the mixture that had prior incubation with PKA as compared with LKB1
(Figure 3, n=6, p < 0.05). In the western blots, phosphorylation of AMPK was
increased by 51% compared to LKB1 alone.
To confirm that the AMPKK Kinase effect of PKA was in fact due to the
protein and not other elements in the reaction mixture, a series of experiments using
PKA inhibitor were performed. First, Kemptide was used as a substrate for PKA
phosphorylation to determine the efficacy of the inhibitor. PKA inhibitor effectively
blocked the phosphorylation of Kemptide by PKA (Figure 4, n=6, p < 0.05). Then as
in the experiments presented in Figure 2, an assay for AMPK activity was conducted
using PKA as an AMPKKK for LKB1 compared with an assay wherein the PKA was
previously incubated with the PKA inhibitor. PKA that had been incubated with an
inhibitor showed no significant AMPKKK activity whereas PKA alone showed 19%
more phosphorylation of AMPK than the mixture with the inhibitor and 25% more
than LKB1 alone (Figure 5, n=6, p < 0.05).
To determine if the stimulatory effect of PKA on AMPKK activity could be
demonstrated in intact muscle, rat epitrochlearis muscles were incubated without
additions, with AICAR to activate AMPK, with epinephrine to activate PKA or with
combinations of AICAR and epinephrine. As determined by immunoprecipitation, the
groups treated with AICAR, 1 uM epinephrine, 1 uM epinephrine/AICAR, 25 nM
epinephrine, and 25 nM epinephrine/AICAR all saw significant activation of AMPK
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compared with controls (Figure 6, n=8, p < 0.05). The results of the AMPK activity
assay were then verified with a blot for P-AMPK. Compared to controls, treatments
with AICAR, 1 uM epinephrine/AICAR, and 25 nM epinephrine/AICAR all caused
significant phosphorylation of the threonine-172 site on AMPK. The 1 uM and 25 nM
epinephrine treatments had significant decreases in phosphorylation at the same site
(Figure 8, n=6, p < 0.05). To corroborate the results of the blot for P-AMPK, a blot
for phosphoserine-79 ACC (P-ACC) was performed. Significant phosphorylation of
the site was seen in all the same treatments as in the blot for P-AMPK. However,
there was no significant change in phosphorylation of serine-79 in the 1 uM and 25
nM epinephrine treatments (Figure 9, n=6, p < 0.05).
To verify that incubation with epinephrine resulted in increased amounts of
PKA activity in the tissue, a blot for P-CREB, a downstream target of PKA was
performed. All treatments except for the 25 nM epinephrine group caused increases in
phosphorylation of the protein (Figure 9, n=6, p < 0.05).

Discussion
These results demonstrate that PKA can act as an AMPKK Kinase
(AMPKKK) by means of its ability to phosphorylate serine residues on LKB1 thus
stimulating its AMPKK activity. This was demonstrated both in assays and blots for
phosphorylation of the threonine-172 site on the alpha subunit of AMPK. Increases of
up to 51% in phosphorylation of this site due to prior phosphorylation of LKB1 by
PKA were seen.
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Incubating LKB1 with PKA showed the greatest effect on AMPK in activity
assays, increasing activity by about 33%. Western blots using the same concentration
of PKA resulted in an average increase in AMPK activation of nearly 51%.
It appears that the effect of PKA in increasing AMPK activity is due to its
effect on LKB1 and not any direct action on the AMPK molecule. In the experiments
shown in Figures 2 and 5, it can be seen that the same concentration of PKA that was
incubated with LKB1 was also incubated with AMPK directly and no phosphorylation
occurred. Additionally, experiments using PKA Inhibitor eliminated PKA’s ability to
act as an AMPKKK.
The mechanism by which PKA may be increasing the AMPKK activity of
LKB1 is unclear. LKB1 and calmodulin-dependent protein kinase kinase (CAMKK)
are the only AMPK Kinases that have been identified although CAMKK’s role in
skeletal muscle is not well-defined (11). Although the LKB1 complex may be
regulated by upstream elements such as PKA, a number of studies suggest that the
protein is constitutively active (8). Thus, it is likely that the kinase activity of the
LKB1 complex may be regulated at the substrate level. Of the other 12 AMPK-related
kinases, the LKB1/STRAD/MO25 complex phosphorylates and activates 11 of them
(19). The LKB1 complex is not activated by contraction but contraction results in
phosphorylation of AMPK giving evidence that the AMPKK activity of LKB1 is
subject to target-specific control (13, 26).
Accordingly, it is possible that phosphorylation by PKA may not necessarily
regulate the LKB1 complex itself but rather allow for better interaction between LKB1
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and AMPK. It is postulated there is some kind of covalent modification induced by
phosphorylation that begins to affect AMPKK activity.
Although there is a marked increase in phosphorylation of AMPK in vitro
when LKB1 is previously phosphorylated by PKA, this effect was not seen in the
epitrochlearis tissue. Phosphorylation of CREB, a downstream target of PKA, was
utilized as an index of PKA activation. Of the five treatments to which the tissues
were subjected, all but the tissues exposed to 25 nM epinephrine experienced
significant increases in PKA activity. The fact that P-CREBx increased in muscles
exposed only to AICAR implies that AMPK may enhance activation of PKA in the
absence of catecholamines. However, AMPK activation was only significant in
tissues that had been treated with AICAR. Compared to the control, epinephrine alone
did not result in significant activation of AMPK. The combination of AICAR and
epinephrine also did not result in significant activation of AMPK any more than
AICAR alone.
Whether used alone or in combination with AICAR, epinephrine did not result
in increased AMPK activation in any of the tissues. The exception being noted in the
immunoprecipitation experiment (Figure 6) wherein there was marginal activation of
AMPK by 1 uM epinephrine that was just above the standard error. One study has
shown stimulatory effects on AMPK in skeletal muscle cells mediated by α1adrenoceptors, but not α2- or β− adrenoceptors (15). Another study has indicated that
in brown adipocytes β- adrenoceptors, but not α-adrenoceptors, stimulate AMPK (16).
Additional work reports that the α- adrenergic agonist, phenylephrine, stimulates α2

31

AMPK activity in soleus muscle tissue (22). The results of this study did not show an
increase in AMPK activity as a result of incubation with epinephrine.
PKA’s ability to act as an AMPKKK as witnessed in vitro may not have been
seen in the muscle tissue because the PKA is not regulating the LKB1 molecule itself
but rather involved in enhancing the LKB1-AMPK interaction. Resultant cellular
concentrations of PKA due to the tissue treatments may have been outside the ranges
that resulted in the stimulatory effect on the AMPKK activity of LKB1 seen in vitro.
In conclusion, we found that phosphorylation by PKA can increase the
AMPKK activity of LKB1-STRAD-MO25 in vitro. This effect was witnessed within
specific concentration ranges of PKA. The stimulatory effect of PKA phosphorylation
of LKB1-STRAD-MO25 was not observed in intact incubated muscle stimulated with
AICAR and epinephrine. It is postulated that phosphorylation by PKA may act to
enhance LKB1-AMPK interaction and thus achieve its effect.
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Figure Legends
Figure 1
Phosphorylation of LKB1 by PKA was verified by western blot showing relative
quantities of phosphoserine-428 (P-LKB1) after incubation of PKA with LKB1.
Optimal phosphorylation was determined to occur with 0.10 phosphorylating units of
PKA. The buffer value is normalized to 1 (n=6, p < 0.05, * =significantly more than
buffer).

Figure 2
Significant additional AMPK phosphorylation occurs when 0.10 units of PKA is
incubated with LKB1 prior to incubation with AMPK as compared to when AMPK is
incubated with LKB1 alone (n=12, p < 0.05, * = significantly more than LKB1 alone).

Figure 3
The results shown in Figure 2 are validated by western blot showing relative quantities
of phosphothreonine-172 AMPK (P-AMPK) after incubation with LKB1 and
incubation with LKB1 that has been phosphorylated by 0.10 units of PKA. Additional
significant phosphorylation of the AMPK molecule is achieved when LKB1 is
incubated with 0.10 units of PKA prior to incubation with AMPK (n=6, p < 0.05, * =
significantly more than LKB1 alone).

Figure 4
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As determined by assay using the substrate Kemptide, it was found that Kemptide is
not phosphorylated by PKA when PKA is incubated with PKA Inhibitor prior to
incubation with Kemptide (n=6, p < 0.05, * = significantly more than Inhibitor alone).

Figure 5
As determined by assay using SAMS peptide, incubation of PKA with PKA Inhibitor
prior to incubation with LKB1 eliminates the additional activation of AMPK seen in
the experiment shown in Figures 2 and 3. Thus it is shown that the effect is due to
PKA and not other elements in the reaction mixture (n=6, p < 0.05, * = significantly
more than LKB1 alone, + = significantly less than LKB1 alone).

Figure 6
Immunoprecipitaiton to determine AMPK activity in rat epitrochlearis muscle tissue.
The AMPK activity of 1 uM Epinephrine + AICAR and 25 nM Epinephrine + AICAR
compared with AICAR alone is not statistically significant (n=8, p < 0.05, *
=significantly more than control).

Figure 7
Activation of AMPK was measured by western blot showing relative quantities of
phosphothreonine-172 AMPK (P-AMPK). Significant phosphorylation occurred in
the AICAR, 1 uM Epinephrine + AICAR, and 25 nM Epinephrine + AICAR
treatments. Phosphorylation was significantly less than control in the 1 uM
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Epinephrine and 25 nM Epinephrine groups (n=6, p < 0.05, * = significantly more
than control, + = significantly less than control).

Figure 8
Phosphorylation of Acetyl CoA Carboxylase was measured by western blot showing
relative quantities of phosphoserine-79 ACC (P-ACC). Significant phosphorylation
occurred only in the AICAR, 1 uM Epinephrine + AICAR, and 25 nM Epinephrine +
AICAR treatments (n=6, p < 0.05, * = significantly more than control).

Figure 9
Phosphorylation of CREB was determined by western blot for relative quantities of
phospho-CREB. Significant phosphorylation occurred in all treatments except for the
25 nM Epinephrine group (n=6, p < 0.05, * = significantly more than control).
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Figure 6
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Figure 7
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Figure 8
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Figure 9
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